Director, Investor Relations
Novavax, Inc. | |
401(k)
| |
United States, Maryland, Gaithersburg | |
Mar 25, 2026 | |
|
Novavax is global biotechnology company, committed to developing life-saving innovations that reach billions around the world. Our corporate growth strategy focuses on maximizing the impact of our cutting-edge technology by forging strategic partnerships for our R&D assets and our Matrix-M adjuvant to drive vaccine innovation that protects the health of people. By leveraging our science, our technology and our people, we will innovate and collaborate to tackle the world's most significant health challenges. Novavax is seeking a strategic, forward-thinking Director, Investor Relations to lead and evolve a best-in-class investor relations program for a publicly traded biotechnology company. Reporting to the Executive Vice President (EVP) & Chief Financial Officer, this highly visible role partners closely with the executive leadership team to articulate the company's scientific, data driven, and financial narrative; strengthen engagement with the investment community; and support long-term shareholder value creation. This role requires strong capital markets expertise, scientific fluency, and the ability to translate complex data into clear, compelling investment messages. How You'll Make an Impact
Required Knowledge, Skills, and Abilities
Education, Experience, Licenses & Certifications
Our Mission By leveraging our science, our technology and our people, we will innovate and collaborate to tackle the world's most significant health challenges. Our Vision We envision a world where our technology is amplified to touch the lives of billions, sparking transformation in global health. Our Values Integrity, Collaboration, Innovation, Agility and Accountability sit at the heart of our culture. They express the mindset and behaviors that guide how we show up, how we work together and how we create impact - for patients, partners and each other. Our Footprint Novavax is proudly headquartered in the USA with main offices in Gaithersburg, Maryland. We conduct R&D and manufacturing for our Matrix-M adjuvant in Uppsala, Sweden. | |
401(k)
Mar 25, 2026